William Blair Weighs in on TransMedics Group, Inc.’s Q3 2025 Earnings (NASDAQ:TMDX)

TransMedics Group, Inc. (NASDAQ:TMDXFree Report) – Stock analysts at William Blair upped their Q3 2025 earnings per share (EPS) estimates for TransMedics Group in a report released on Tuesday, April 30th. William Blair analyst R. Daniels now expects that the company will post earnings of $0.12 per share for the quarter, up from their prior forecast of $0.09. The consensus estimate for TransMedics Group’s current full-year earnings is ($0.14) per share. William Blair also issued estimates for TransMedics Group’s FY2025 earnings at $0.27 EPS.

TMDX has been the topic of several other reports. Piper Sandler reiterated an “overweight” rating and set a $120.00 target price (up from $95.00) on shares of TransMedics Group in a research report on Wednesday. Canaccord Genuity Group upped their price target on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday. JPMorgan Chase & Co. lifted their price target on shares of TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday. Oppenheimer boosted their price objective on shares of TransMedics Group from $105.00 to $125.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, TD Cowen lifted their target price on TransMedics Group from $100.00 to $130.00 and gave the company a “buy” rating in a report on Wednesday. One equities research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $119.00.

View Our Latest Stock Analysis on TransMedics Group

TransMedics Group Stock Up 5.8 %

TMDX stock opened at $124.44 on Thursday. TransMedics Group has a one year low of $36.42 and a one year high of $124.52. The stock has a market capitalization of $4.07 billion, a P/E ratio of -366.00 and a beta of 1.87. The company has a 50 day moving average price of $84.64 and a two-hundred day moving average price of $76.26. The company has a debt-to-equity ratio of 3.69, a quick ratio of 8.49 and a current ratio of 9.30.

TransMedics Group (NASDAQ:TMDXGet Free Report) last released its quarterly earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.40. The company had revenue of $96.90 million for the quarter, compared to analysts’ expectations of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 8.29%. The firm’s revenue for the quarter was up 132.9% compared to the same quarter last year. During the same period last year, the company earned ($0.08) EPS.

Insiders Place Their Bets

In other news, insider Tamer I. Khayal sold 15,512 shares of the stock in a transaction that occurred on Tuesday, April 9th. The stock was sold at an average price of $90.45, for a total transaction of $1,403,060.40. Following the completion of the transaction, the insider now directly owns 25,185 shares in the company, valued at approximately $2,277,983.25. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. In other news, insider Tamer I. Khayal sold 15,512 shares of the company’s stock in a transaction dated Tuesday, April 9th. The shares were sold at an average price of $90.45, for a total value of $1,403,060.40. Following the sale, the insider now owns 25,185 shares in the company, valued at approximately $2,277,983.25. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Edward M. Basile sold 7,157 shares of the stock in a transaction dated Tuesday, February 6th. The stock was sold at an average price of $86.38, for a total transaction of $618,221.66. Following the transaction, the director now directly owns 8,350 shares in the company, valued at approximately $721,273. The disclosure for this sale can be found here. Insiders have sold 102,078 shares of company stock worth $8,691,221 in the last three months. 7.00% of the stock is owned by insiders.

Hedge Funds Weigh In On TransMedics Group

Several large investors have recently added to or reduced their stakes in the company. FMR LLC raised its holdings in shares of TransMedics Group by 42.5% during the third quarter. FMR LLC now owns 4,714,870 shares of the company’s stock worth $258,139,000 after purchasing an additional 1,407,171 shares during the period. Vanguard Group Inc. raised its stake in TransMedics Group by 2.8% during the fourth quarter. Vanguard Group Inc. now owns 1,865,115 shares of the company’s stock worth $147,214,000 after acquiring an additional 50,673 shares during the period. Eventide Asset Management LLC lifted its holdings in TransMedics Group by 7.4% in the fourth quarter. Eventide Asset Management LLC now owns 994,240 shares of the company’s stock worth $78,475,000 after acquiring an additional 68,884 shares during the last quarter. Sandhill Capital Partners LLC grew its holdings in shares of TransMedics Group by 4.2% during the fourth quarter. Sandhill Capital Partners LLC now owns 763,201 shares of the company’s stock valued at $60,239,000 after purchasing an additional 30,591 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its holdings in shares of TransMedics Group by 91.4% during the third quarter. Bank of New York Mellon Corp now owns 760,099 shares of the company’s stock valued at $41,615,000 after purchasing an additional 363,012 shares during the last quarter. 99.67% of the stock is currently owned by institutional investors.

About TransMedics Group

(Get Free Report)

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.

Featured Articles

Earnings History and Estimates for TransMedics Group (NASDAQ:TMDX)

Receive News & Ratings for TransMedics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransMedics Group and related companies with MarketBeat.com's FREE daily email newsletter.